Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Alumis Inc. - Common Stock (NQ: ALMS ) 12.27 +0.05 (+0.45%) Streaming Delayed Price Updated: 12:13 PM EDT, Aug 9, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Alumis Inc. - Common Stock Alumis Initiates ONWARD Phase 3 Clinical Program Evaluating ESK-001, an Oral TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis July 29, 2024 From Alumis Inc. Via GlobeNewswire Newly-Listed Psoriasis-Focused Alumis Attracts Analysts' Attention With Promising Lead Program And Modest Valuation July 24, 2024 Guggenheim Partners initiated coverage on Alumis, highlighting its lead asset ESK-001, a TYK2 inhibitor for plaque psoriasis and systemic lupus erythematosus. With upcoming Phase 3 trials and no JAK... Via Benzinga Ardent Health Slips After Downsized IPO July 21, 2024 Shares of Ardent Health slipped in their trading debut on Thursday after the hospital operator reduced its initial public offering from its proposed size and priced below the marketed range. Via Talk Markets Immune Disease-Focused Alumis Raises $250M In Downsized Initial Public Offering June 28, 2024 Alumis priced its IPO at $16/share, raising $210 million with 13.13 million shares. Trading begins June 28, 2024. Alumis develops oral therapies for immune-mediated diseases, with its lead candidate... Via Benzinga Topics Initial Public Offering Exposures Securities Market Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
